Vernalis plc (VER) Receives Buy Rating from Stifel Nicolaus
Several other equities analysts have also recently issued reports on VER. Panmure Gordon reissued a buy rating and set a GBX 76 ($0.99) target price on shares of Vernalis plc in a research note on Friday, July 8th. Shore Capital reissued a house stock rating on shares of Vernalis plc in a research note on Friday, July 8th. Canaccord Genuity reissued a buy rating and set a GBX 84 ($1.10) target price on shares of Vernalis plc in a research note on Tuesday, September 6th. Finally, N+1 Singer reissued a hold rating and set a GBX 46 ($0.60) target price on shares of Vernalis plc in a research note on Thursday. One equities research analyst has rated the stock with a hold rating and three have issued a buy rating to the stock. Vernalis plc has an average rating of Buy and a consensus price target of GBX 73 ($0.95).
Shares of Vernalis plc (LON:VER) opened at 41.49 on Thursday. The company has a 50-day moving average price of GBX 43.70 and a 200-day moving average price of GBX 45.74. Vernalis plc has a 52-week low of GBX 31.00 and a 52-week high of GBX 79.00. The stock’s market capitalization is GBX 184.68 million.
Vernalis plc Company Profile
Vernalis plc is a commercial-stage pharmaceutical holding company. The Company is engaged in the research, development and commercialization of pharmaceutical products for a range of medical disorders. The Company has two marketed products: Tuzistra XR in the United States prescription cough cold market, and frovatriptan, an acute treatment for migraine.
Receive News & Stock Ratings for Vernalis plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vernalis plc and related stocks with our FREE daily email newsletter.